Understanding drug resistance of targeted BRAF inhibitors in late-stage melanoma [ 2014 - ]

Research Grant

Researchers: Dr Ken Dutton-Regester (Principal investigator)

Brief description Late-stage melanoma is an aggressive skin cancer for which traditional treatment strategies such as chemotherapy are ineffective. Recently, a new class of targeted drugs (BRAF inhibitors) has become the standard of care for a subset of melanoma patients; however, long term treatment success is complicated by drug resistance. This study will identify the causes of resistance with the purpose to improve targeted drug strategies and increase survival rates for late-stage melanoma patients.

Funding Amount $355,028.00

Funding Scheme Early Career Fellowships

Notes CJ Martin Biomedical ECF